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Increased activation of the central benzodiazepine receptor Hepatic encephalopathy (HE) is a disabling consequence
(BZR) appears to play an important role in hepatic encepha- of advanced liver disease, but the pathophysiology of HE
lopathy (HE). However, there is controversy regarding remains unclear. Several lines of evidence support a role
whether the density or affinity of BZRs is altered. A previous for increased activity of the central benzodiazepine receptor
positron emission tomography (PET) study using the BZR (BZR) in HE. The BZR is a component of the g-aminobutyric
antagonist [11C]flumazenil (FMZ) found two- to threefold acid (GABAA) chloride channel. Activation of the BZR results
greater cerebral cortical tracer uptake in recurrent HE, but in an increased sensitivity of the GABAA receptor to agonists
did not account for impaired FMZ metabolism due to liver and increased activity of the GABAA chloride channel.
1
disease or assess the relative contributions of tracer delivery Increases in the density of GABAA and BZRs have been
versus BZR binding. We hypothesized that correcting for shown in animals with hepatic failure induced by galactos-
these factors would affect estimations of BZR binding in HE. amine.2,3 This model of HE also showed changes in the affin-
Nine patients with recurrent HE and 13 age-comparable con- ity of the GABAA receptor with increasing severity of HE.
4
trols were studied with [11C]FMZ PET. After intravenous ad- Finally, the central nervous system concentrations of endoge-
ministration of [11C]FMZ, arterial blood samples were col- nous BZR agonists are elevated in rat and rabbit models of
lected, and PET images were acquired over 60 minutes. FMZ HE in fulminant hepatic failure.5-7 An increase in BZR tone
transport and binding maps were calculated for each subject has been implicated in HE in humans also. Endogenous ben-
by using a physiological tracer kinetic model. In agreement zodiazepine-like ligand (‘‘endozapine’’) concentrations are
with the previous report, we found that FMZ reached a much increased in plasma, cerebrospinal fluid, and brain tissue of
higher level and was retained longer in the HE cerebral cortex patients with chronic HE.8,9 The source of these circulating
despite similar total blood radioactivity levels in the two endogenous factors has not been determined, although co-
groups. However, the patients showed impaired hepatic me- lonic flora have been proposed as a possible source.9 Addi-
tabolism of FMZ. After physiological modeling incorporating tionally, [11C]flumazenil (FMZ) has been shown in clinical
these data, significant increases in BZR binding were found studies to reverse both acute and chronic HE.10-15
in the thalamus (13%), cerebellum (20%), and pons (23%). Although activation of central BZRs appears to contribute
There were minor, statistically insignificant increases in cere- to HE, the status of the receptor itself is unclear. There has
bral cortical (10%), putamen (12%), and whole brain (12%) been controversy about whether part of the increase in BZR
BZR binding in patients with recurrent HE. These findings activity in HE is due to a change in the density or agonist
are in general agreement with results of autopsy studies, con- affinity of the BZR. Samson et al.16 reported the results of a
firming a lack of major increases in cortical or basal ganglial positron emission tomography (PET) study using the BZR
BZR binding in HE. They emphasize that physiological tracer antagonist [11C]FMZ in 4 patients with recurrent HE in
modeling should be used and altered peripheral radioligand which they found a two- to threefold increase in cerebral
metabolism considered in future PET studies of HE. (HEPA- radioactivity compared with normal control subjects. They
TOLOGY 1997;26:277-282.) attributed the findings to an increase in density of central
BZRs. However, Butterworth et al.,17 in a carefully conducted
postmortem study, found no increase in the affinity or den-
sity of GABA or BZRs in the brains of patients with alcoholicAbbreviations: HE, hepatic encephalopathy; BZR, benzodiazepine receptor; GABA,
cirrhosis who died with grade IV HE.g-aminobutyric acid; FMZ, flumazenil; PET, positron emission tomography; TIPS,
transjugular intrahepatic portosystemic shunt; K1, tracer transport from blood to brain; The report from Samson et al.16 states that blood 11C kinet-
DV, distribution volume; ROI, region of interest. ics were ‘‘roughly’’ similar between HE and control subjects,
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TABLE 1. Clinical Details of 9 Patients With Recurrent HE Studied With [11C]FMZ PET
PT Albumin Bilirubin Child-Pugh
Patient Age/Sex Etiology (s) (g/dL) (mmol) Ascites Encephalopathy Score24 Shunt
1 33/M Glycogen-storage 14 3.6 17 Mild Mild 5 TIPS
disease type 3
2 38/M Ethanol 13.6 3.3 17 Mild Mild 6 TIPS
3 56/F Primary sclerosing 13.7 3.6 31 Mild Moderate 6 TIPS
cholangitis
4 62/F Hepatitis C 14.1 3.4 20 Moderate Moderate 8 TIPS
5 60/F Cryptogenic 15.8 3.0 49 Moderate Moderate 9 No
6 49/M Cryptogenic 15.2 3.5 22 Marked Moderate 9 No
7 53/F Autoimmune 12.4 2.8 54 Mild Severe 11 Distal splenorenal
chronic hepatitis
8 53/M Ethanol 14.6 3.0 51 Marked Moderate 11 TIPS
9 52/M Ethanol 20.5 2.1 75 Marked Moderate 14 No
Abbreviation: PT, prothrombin time.
for withdrawal of timed blood samples. A dynamic series of PETtion would then result in overestimation of BZR density. We
images was obtained over 60 minutes together with arterial bloodconsidered that this was probably the reason for the increase
samples after the bolus injection of approximately 20-50 mCi ofin brain FMZ activity reported previously. In the present
[11C]FMZ, containing less than 27 g tracer mass. The time coursesstudies, we have extended these earlier FMZ PET observa-
of the arterial concentration of unmetabolized [11C]FMZ and itstions with the application of a quantitative tracer kinetic
labeled, polar metabolites were determined chromatographically as
method for estimation of FMZ binding to GABAA receptors described previously.21
that accounts for effects on peripheral radiotracer metabolism The blood and PET data were analyzed according to a two-com-
by direct measurement and chromatography of arterial partment, two-parameter tracer kinetic model, resulting in pixel-
plasma.21-23 by-pixel parametric images of tracer transport (K1) and binding
(represented by the total tracer tissue distribution volume [DV]).
PATIENTS AND METHODS Prior studies have identified the physiological sensitivity and speci-
ficity of these parameters and indicate a lack of confounding effectsSubjects. Nine patients with recurrent HE and 13 age-comparable
of cerebral blood flow on estimates.22,23,26controls were studied. The patients were all undergoing evaluation
After calculation of the K1 and DV images, we spatially deformedfor liver transplantation and took lactulose daily for control of symp-
individual brains to a common reference anatomic format. The de-toms of chronic HE. Clinical details of these 9 patients are presented
formation procedure makes use of the K1 image for anatomic featurein Table 1. The severity of liver disease was estimated using the
definition and adjusts both the scale and the shape of each brainChild-Pugh score.24 Three patients had liver disease from ethanol,
with sequential application of linear and nonlinear thin-plate splinetwo had cryptogenic cirrhosis, and one each had autoimmune hepa-
deformations as described previously.27 Average images of K1 andtitis, hepatitis C, primary sclerosing cholangitis, and type III glyco-
of DV were then constructed for the HE and control groups. Thesegen-storage disease. Cirrhosis is an unusual sequela of type III glyco-
were sampled according to prospectively designated regions of in-gen-storage disease, and the clinical details of this patient have been
terest (ROIs), and were additionally explored on a voxel-by-voxelreported previously.25 Five patients had transjugular intrahepatic
basis for unanticipated focal differences.28portosystemic shunts (TIPS), and one had a distal splenorenal shunt
Statistics. Blood FMZ and metabolism indices and brain ROI datafor control of variceal hemorrhaging. Patency of the TIPS was con-
were assessed with pairwise Student’s t tests. Exploratory pixel-by-firmed by Doppler ultrasonography within 2 weeks of the study.
pixel analyses employed correction for multiple parallel compari-No patient had received sedatives for at least 5 weeks before the
sons, assuming 9-mm3 resolution in the reoriented images, corre-study. All 9 had had recurrent episodes of acute or chronic HE,
sponding to approximately 980 independent gray-matter resolutionalthough none had greater than grade I HE on the day of the study.
elements in the PET images.28 A statistical threshold of P õ .05There were 7 men and 6 women in the control group, all of
was used to identify significant group differences in all analyses.whom were free of significant general medical, neurological, and
psychiatric illness and had no history of first-degree relatives with
RESULTSfamilial neurological or psychiatric disease. The median age was 59
years (mean SD, 57 { 7 years; range, 45-65 years) and was not
The integrated arterial 11C activity from unmetabolized,significantly different from that in the patient group.
intact [11C]FMZ was similar for the two groups over the hourAll subjects were screened to exclude history of head trauma with
of the PET imaging study (Table 2). However, the arterialloss of consciousness, recent drug or alcohol abuse or dependence,
smoking, excessive consumption of caffeine, and, in the case of 11C activity due to polar, radiolabeled, FMZ metabolites was
control subjects, use of centrally acting medications within 12 significantly greater in the control group. When arterial
months of participation. The studies were approved by the Univer- tracer time courses were examined in detail, substantial ele-
sity of Michigan Institutional Review Boards governing studies in- vations of the terminal FMZ concentrations were observed
volving human subjects and the use of radioactivity in humans. in HE, despite similar total arterial radioactivity levels in
Written informed consent was obtained for all studies. the two groups (Fig. 1). At 60 minutes postinjection, the
PET Imaging. The blood-brain transport and binding of FMZ to
percentage of arterial 11C activity due to authentic FMZ wasthe central BZR on the GABAA-chloride ionophore complex were
almost 70% higher in the patients than in the control group.determined as previously described.21 In brief, subjects were posi-
Inspection of cerebral tracer time activity curves revealedtioned supine in the gantry of a Siemens/CTI 931/08-12 tomograph
characteristic shape differences between HE and control sub-(Siemens Gammasonics, Inc., Hoffman Estates, IL) with an antecu-
bital venous catheter for tracer injection and a radial arterial catheter jects, with relatively greater peak tracer uptake and more
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TABLE 2. Integrated Activity of [11C]FMZ and Metabolites Over concentrations of unmetabolized tracer are used in physio-
Duration of Study logical estimations of [11C]FMZ transport and BZR binding,
the two- to threefold increases in binding suggested by thePatients Controls P
cerebral activity levels alone are now shown to reflect pre-
Flumazenil dominantly the effects of elevated and protracted blood tracer
(% dose/mL/kg) min 0.570 { 0.144 0.528 { 0.270 NS availability in HE. When the arterial plasma concentration
Metabolites
of unmetabolized [11C]FMZ was used in the physiological(% dose/mL/kg) min 0.378 { 0.198 0.768 { 0.312 .002
calculations of [11C]FMZ transport and binding, there wereRatio of metabolites/
trends toward increased global (whole brain), cerebral corti-authentic FMZ 0.62 { 0.27 1.6 { 0.66 õ.002
cal, and basal ganglial binding in HE that were not statisti-% arterial 11C activity at
60 min due to cally significant and are considerably lower in magnitude
authentic FMZ 0.44 { 0.15 0.26 { 0.08 .007 than previously reported. Failure to correct cerebral tracer
data for altered blood levels in this instance results in a
NOTE. Values are means { SD.
substantial overestimation of FMZ binding, emphasizing the
need to chromatographically determine arterial ligand con-
centrations in future PET studies of HE.
protracted retention in HE (Fig. 1C), similar to those pre- We found a trend toward increased global (whole brain)
viously reported.16 However, after compartmental physiolog-
ical model applications to the activity curves, there were no
significant differences either in whole brain or in regional
FMZ K1 in HE versus the normal control groups (Table 3).
There was a trend toward increased whole brain average
[11C]FMZ DV in patients with recurrent HE that was not
statistically significant (P Å .065; Table 3, Fig. 2). Addition-
ally, there was no correlation between the severity of liver
disease (Fig. 3) or the presence of a portosystemic shunt
and whole brain [11C]FMZ DV. When specific ROIs were
examined, patients with HE showed modest (13%-23%) but
statistically significant increases in [11C]FMZ DV in the thala-
mus, cerebellum, and pons (Fig. 4, Table 3). Although there
were trends toward increased FMZ DV (10%-12%) in the
putamen and cerebral cortex of the patient group, these were
not statistically significant. The changes in the putamen were
representative of those occurring elsewhere in the basal gan-
glia. The voxel-by-voxel analysis of FMZ DV confirmed that
the largest between-group differences were in the thalamic
and cerebellar regions but did not suggest additional areas of
change that had been overlooked in the a priori ROI analyses.
DISCUSSION
The metabolism of drugs, including tracers such as
[11C]FMZ, may be impaired in patients with recurrent HE.
We found increased arterial FMZ levels in the later phases
of PET imaging sessions and reduced levels of polar FMZ
metabolites in the plasma of patients with HE. These changes
indicate either impaired metabolism of tracer doses of
[11C]FMZ or altered peripheral volumes of distribution for
FMZ and its metabolites. Decreased peripheral FMZ metabo-
lism has recently been reported in patients with advanced
liver disease18,19 and is the most likely explanation for these
FIG. 1. Radiotracer time-activity curves from a patient with HE and achanges. Whereas our patient group showed a trend toward
representative normal control subject. Total arterial plasma radioactivitygreater integrated [11C]FMZ plasma activity over the 60 min- levels (A), chromatographically determined plasma [11C]FMZ levels (B),
utes of the study, the reduction in plasma metabolite activity and temporal neocortical tracer levels (C) are depicted from a 48-year-old
control subject after bolus intravenous injection of 0.16 mCi/kg body wt ofwas more obvious. The most significant effect of altered FMZ
[11C]FMZ (●, solid lines) and from HE patient 9 (see Table 1) after injectionmetabolism was a greater percentage of circulating 11C activ-
of 0.16 mCi/kg (s, dashed lines). Note that the plots of arterial activitiesity attributable to [11C]FMZ in patients than in controls dur-
in (A) and (B) are semilogarithmic. Comparable courses of total arterial
ing the last half of the PET sessions. radioactivity and very distinct cerebral activity curves can be observed. These
Previously reported increases in cerebral cortical curves are similar to the findings of a prior study of [11C]FMZ distribution
in HE.16 However, there is a substantial relative elevation of unmetabolized[11C]FMZ uptake observed with PET in patients with HE
arterial [11C]FMZ, evident within 5 minutes postinjection, that is sustainedhave been interpreted as evidence of increased BZR availabil-
throughout the remainder of the PET session. Kinetic compartmental analy-ity.16 Our data reproduce the prior observation of comparable ses reveal FMZ DV of 5.62 and 6.79 in the temporal cortices of the control
total blood activity levels and distinctly different cerebral and HE subjects, respectively, rather than the threefold binding difference
suggested by the cerebral tracer levels at 60 minutes, evident in C.tracer activities in HE. However, when the arterial plasma
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TABLE 3. [11C]Flumazenil Transport (K1) and Binding (DV) for Whole Brain and Selected Regions of Interest in Control and Patient Groups
FMZ Transport (K1) FMZ Binding (DV)
Patients
Brain Region Controls ({SD) Patients ({SD) Controls ({SD) ({SD)
Cerebral Cortex 0.349 (0.077) 0.392 (0.062) 5.37 (0.72) 5.92 (0.86)
Putamen* 0.368 (0.082) 0.420 (0.068) 3.55 (0.53) 3.96 (0.61)
Thalamus* 0.448 (0.106) 0.509 (0.072) 3.99 (0.62) 4.53 (0.53)†
Cerebellum* 0.371 (0.081) 0.377 (0.055) 4.04 (0.56) 4.84 (0.69)‡
Pons* 0.319 (0.076) 0.344 (0.062) 1.68 (0.36) 2.07 (0.39)†
Global Gray matter* 0.330 (0.066) 0.347 (0.047) 5.10 (0.65) 5.71 (0.82)#
NOTE. Parametric estimates of FMZ transport (K1) and binding (DV) from a 2-compartment kinetic model
21 were sampled from stereotactically-
placed ROI as described previously.28 Values represent means and SD for K1 (mL plasma/mL brain/min) or DV (mL plasma/mL brain). Volume-weighted
average of cerebral cortical activity in the scanned field-of-view.
* Volume-weighted average of cerebral gray matter in the scanned field-of-view as determined on the basis of K1 values.
28
† P õ 0.05, ‡P õ 0.01, #P Å 0.065 vs. control.
FMZ binding in HE that was not statistically significant and studies have also failed to detect a significant increase in the
density of BZRs or GABAA receptors in HE.
3,29,30was not correlated with the severity of liver disease in indi-
vidual patients as gauged by their Child-Pugh scores.24 It In contrast to cortical and basal ganglia BZR binding, we
detected statistically significant increases in [11C]FMZ bind-should be noted, however, that 6 of the 9 patients had porto-
sytemic shunts, and the lack of correlation may be due to ing in the thalamus, pons, and cerebellum. These localized
increases in [11C]FMZ binding could be due to a variety ofconfounding favorable effects of the shunts on ascites and
hepatic biochemical function. Additionally, the multifactorial factors. Only unbound (free) plasma FMZ is available to
cross the blood-brain barrier. From this pool, only unmetab-nature of exacerbations of chronic HE is well recognized,
and alterations in central BZR density or affinity might reflect olized FMZ has been shown to cross the intact blood-brain
barrier.20 FMZ has a relatively low binding of plasma proteinrecent biochemical fluctuations to a greater extent than the
long-term effects of hepatic insufficiency. Nevertheless, our binding; approximately 40% is plasma protein bound in nor-
mal volunteers.31 Although patients with advanced liver dis-data do not support a major role of elevated whole brain BZR
density in the clinical phenomenology of HE responsiveness ease have been shown to have reduced plasma protein bind-
ing of [11C]FMZ,18 we believe that the potential increase ofto BZR antagonists. We found insignificant, minor trends
toward increased FMZ binding in the cerebral cortex and free plasma [11C]FMZ in the patient group has not had a
major impact on our data. If increased free FMZ were im-basal ganglia of patients with HE. Our binding data are thus
in general agreement with the findings of the autopsy study portant in distinguishing our groups, we would expect global
rather than regional effects on DV. Furthermore, effects onof Butterworth et al.,17 which reported a lack of change in
either the density or the affinity of BZRs in the cerebral both blood-brain transport (K1) as well as FMZ binding (DV)
should be observed in this instance. Our data indicate sub-cortex or caudate nucleus of patients who died of HE. Animal
stantial regional variations in DV increases, from only 10%
in the cerebral cortex to more than 20% in the pons and
cerebellum and reveal only minor effects on K1 (2%-14%)
that appear maximal in the basal ganglia and thalamus, and
least in the cerebellum where DV is most significantly in-
creased. This means that significant permeability changes in
the blood-brain barrier are unlikely.
FIG. 3. Whole brain [11C]FMZ DV vs. Child-Pugh score.24FIG. 2. Whole brain [11C]FMZ DV in patient and control groups.
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FIG. 4. Group summation analyses of BZR
binding in control and HE subjects. [11C]FMZ
DV maps from individual subjects were ana-
tomically standardized and summed, resulting
in group mean binding maps from patients (top
row) and control subjects (middle row). Voxel-
by-voxel comparison results in a t-statistical
map of between-group differences (bottom
row). Transaxial images, oriented parallel to the
anterior commissure–posterior commissure
line, are depicted from supraventricular (left
column) to posterior fossa (right column) levels.
Parametric FMZ DV (mL plasma/mL brain) and
t values are represented in pseudocolor, ac-
cording to the scale. Largest changes in FMZ
DV are apparent in the cerebellum (right image
column), whereas highest t values are observed
in the ventral thalamus/hypothalamus (middle
column) and cerebellum. Although the cerebel-
lar, thalamic, and pontine DV changes are sta-
tistically significant in prospective ROI analy-
ses, none of the voxel-by-voxel changes exceed
the adjusted t threshold corresponding to the
P õ .05 level of significance (calculated t
threshold, 6.97).
The major pathway for metabolism of FMZ in normal hu- density. Previous PET measures of cerebral blood flow and
glucose metabolism in HE have suggested subcortical in-man subjects is via ester hydrolysis, resulting in a carboxylic
acid metabolite designated Ro 15-3890.32,33 Ro 15-3890 is creases, particularly in the cerebellum, thalamus, and cau-
date.34 Although we find no evidence of significant FMZ DVmore polar than FMZ and is therefore unable to cross the
blood-brain barrier. Persson et al.20 directly verified this pre- change in the caudate nucleus, the overlap of our binding
data with the metabolic changes in these regions suggestsdiction in studies of the cerebral uptake of [11C]Ro 15-3890
in healthy volunteers, demonstrating no detectable entry into that they may be preferentially involved in the cerebral re-
sponse to hepatic failure.the brain after its systemic administration. Furthermore, we
have confirmed directly in rats that the major radioactive In conclusion, we have shown that there is no significant
increase in whole brain or in cerebral cortical [11C]FMZ bind-metabolites of [11C]FMZ do not enter the brain.21 Formation
of a hydroxyl ester at the same position, or N-demethylation ing in patients with recurrent HE, although there are regional
increases in the thalamus and cerebellar cortex. These re-(potentially resulting in 11CO2), are both theoretical meta-
bolic pathways for FMZ, but evidence of either of these prod- gional changes are most likely a result of increases in BZR
density, but parallel or independent increases in BZR affinityucts has not been found in baboon or human [11C]FMZ PET
studies.32,33 Increased permeability of the blood-brain barrier cannot be entirely excluded. Further study is now indicated
to determine the cellular localization and neurochemicalto polar [11C]FMZ metabolites or the production of abnor-
mal, less polar labeled metabolites could lead to increased mechanisms responsible for the regional increases in central
BZR binding in recurrent HE.brain activity, mimicking increased BZR binding in HE. How-
ever, this effect, as with altered plasma protein binding, is
REFERENCESpredicted to result in global changes rather than the regional
1. Jones E, Basile A, Skolnick P. Hepatic encephalopathy, GABA-ergicincreases in FMZ DV we observed.
neurotransmission and benzodiazepine receptor ligands. In: Grisolia S,Our data indicate increased in vivo binding of [11C]FMZ in
ed. Cirrhosis, Hepatic Encephalopathy, and Ammonium Toxicity. Newdiscrete subcortical brain regions, particularly the cerebellar York: Plenum, 1990:121-135.
cortex and thalamus, in HE. Under conditions of trace bind- 2. Baraldi M, Zeneroli ML, Ventura E, Penne A, Pinelli G, Ricci P, Santi
M. Supersensitivity of benzodiazepine receptors in hepatic encephalopa-ing site occupancy, as conducted in our studies, the DV
thy due to fulminant hepatic failure in the rat: reversal by a benzodiaze-binding measure is proportional to the ratio of binding site
pine antagonist. Clin Sci 1984;67:167-175.density (Bmax) to affinity (Kd).21,23 Thus, our findings could
3. Schafer DF, Fowler JM, Munson PJ, Thakur AK, Waggoner JG, Jones E.
indicate either increased binding site numbers or affinity in Gamma-aminobutyric acid and benzodiazepine receptors in an animal
the thalamus and cerebellum. FMZ, a BZR antagonist, is not model of fulminant hepatic failure. J Lab Clin Med 1983;102:870-880.
4. Baraldi M, Zeneroli ZL. Experimental hepatic encephalopathy: changesassociated with shifts in binding affinity induced by other
in the binding of gamma-aminobutyric acid. Science 1982;216:427-429.ligands of the GABAA complex and is not generally recog-
5. Basile AS, Pannell L, Jaouni T, Gammal SH, Fales HM, Jones EA, Skol-nized to show affinity differences in pathological neurode- nick P. Brain concentrations of benzodiazepines are elevated in an ani-
generative states. We thus believe that the most likely expla- mal model of hepatic encephalopathy. Proc Natl Acad Sci U S A 1990;
87:5263-5267.nation for increased FMZ DV in our studies is increased BZR
AID Hepa 0001 / 5p24$$$$$1 07-17-97 16:33:40 hepa WBS: Hepatology
282 MACDONALD ET AL. HEPATOLOGY August 1997
6. Mullen KD, Martin JV, Mendelson WB, Kaminsky-Russ K, Jones EA. of 11C-Ro 15-1788 and its acidic metabolite 11C-Ro 15-3890; PET study
in healthy volunteers. Human Psychopharmacol 1989;4:215-220.Evidence for the presence of a benzodiazepine receptor binding sub-
stance in cerebrospinal fluid of a rabbit model of hepatic encephalopa- 21. Frey KA, Holthoff VA, Koeppe RA, Jewett DM, Kilbourn MR, Kuhl DE.
Parametric in vivo imaging of benzodiazepine receptor distribution inthy. Metab Brain Dis 1989;4:253-260.
7. Basile AS, Gammal SH, Jones EA, Skolnick P. GABAA receptor complex human brain. Ann Neurol 1991;30:663-672.
22. Holthoff VA, Koeppe RA, Frey KA, Paradise AH, Kuhl DE. Differentia-in an experimental model of hepatic encephalopathy: evidence for ele-
vated levels of an endogenous benzodiazepine receptor ligand. J Neuro- tion of radioligand delivery and binding in the brain. J Cereb Blood
Flow Metab 1991;11:745-752.chem 1989;53:1057-1063.
8. Mullen KD, Szauter KM, Kaminsky-Russ K. ‘‘Endogenous’’ benzodiaze- 23. Koeppe RA, Holthoff VA, Frey KA, Kilbourn MR, Kuhl DE. Compart-
mental analysis of [11C]flumazenil kinetics for the estimation of ligandpine activity in body fluids of patients with hepatic encephalopathy.
Lancet 1990;336:81-83. transport rate and receptor distribution using positron emission tomog-
raphy. J Cereb Blood Flow Metab 1991;11:735-744.9. Basile AS, Hughes RD, Harrison PM, Murata Y, Pannell L, Jones EA,
Williams R, et al. Elevated brain concentrations of 1,4-benzodiazepines 24. Pugh RN, Murray Lyon IM, Dawson JL, Pietroni MC, Williams R. Tran-
section of the oesophagus for bleeding oesophageal varices. Br J Surgin fulminant hepatic failure. N Engl J Med 1991;325:473-478.
10. Bansky G, Meier PJ, Riederer E, Walser H, Ziegler WH, Schmid M. 1973;60:646-649.
25. Markowitz AJ, Chen YT, Muenzer J, Delbuono EA, Lucey MR. A manEffects of the benzodiazepine receptor antagonist flumazenil in hepatic
encephalopathy in humans. Gastroenterology 1989;97:744-750. with type III glycogenosis associated with cirrhosis and portal hyperten-
sion. Gastroenterology 1993;105:1882-1885.11. Ferenci P, Grimm G, Meryn S, Gangl A. Successful long-term treatment
of portal-systemic encephalopathy by the benzodiazepine antagonist 26. Ishihara M, Cameron O, Minoshima S, Drury I, Kuhl DE, Frey KA. PET
determinations of benzodiazepine receptor occupancy by unlabelledflumazenil. Gastroenterology 1989;96:240-243.
12. Grimm G, Ferenci P, Katzenschlager R, Madl C, Schneeweiss B, Laggner drugs [Abstract] J Nucl Med 1994;35:141P.
27. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization:AN, Lenz K, et al. Improvement of hepatic encephalopathy treated with
flumazenil. Lancet 1988;2:1392-1394. linear scaling and nonlinear warping of functional brain images. J Nucl
Med 1994;35:1528-1537.13. Scollo-Lavizzari G, Steinmann E. Reversal of hepatic coma by benzodi-
azepine antagonist (Ro 15-1788) [Letter]. Lancet 1985;1:1324. 28. Frey KA, Minoshima S, Koeppe RA, Kilbourne MR, Berger KL, Kuhl
DE. Stereotaxic summation analysis of human cerebral benzodiazepine14. Pomier Layrargues G, Giguere JF, Lavoie J, Perney P, Gagnon S,
D’Amour M, Wells J, et al. Flumazenil in cirrhotic patients in hepatic binding maps. J Cereb Blood Flow Metab 1996;16:409-417.
29. Roy S, Pomier Layrargues G, Butterworth RF, Huet PM. Hepatic enceph-coma: a randomized double-blind placebo-controlled crossover trial.
HEPATOLOGY 1994;19:32-37. alopathy in cirrhotic and portacaval shunted dogs: lack of changes in
brain GABA uptake, brain GABA levels, brain glutamic acid decarboxyl-15. Bansky G, Meier PJ, Ziegler WH, Walser H, Schmid M, Huber M. Rever-
sal of hepatic coma by benzodiazepine antagonist (Ro 15-1788) [Letter]. ase activity and brain postsynaptic GABA receptors. HEPATOLOGY 1988;
8:845-849.Lancet 1985;1:1324-1325.
16. Samson Y, Bernuau J, Pappata S, Chavoix C, Baron JC, Maziere MA. 30. Pappas SC, Levy GA, Gordon VP. Decreased brain GABA binding in a
model of fulminant hepatic failure (FHF) evidence conflicting with theCerebral uptake of benzodiazepine measured by positron emission to-
mography in hepatic encephalopathy [Letter]. N Engl J Med 1987;316: GABA hypothesis for hepatic encephalopathy [Abstract]. HEPATOLOGY
1986;6:1106A.414-415.
17. Butterworth RF, Lavoie J, Giguere JF, Pomier-Layrargues G. Affinities 31. Klotz U, Kanto J. Pharmacokinetics and clinical use of flumazenil (Ro
15-1788). Clin Pharmacokinet 1988;14:1-12.and densities of high-affinity [3H]muscimol (GABAA) binding sites and
of central benzodiazepine receptors are unchanged in autopsied brain 32. Debruyne D, Abadie P, Barre L, Albessard F, Moulin M, Zarifian E, Baron
JC. Plasma pharmacokinetics and metabolism of the benzodiazepinetissue from cirrhotic patients with hepatic encephalopathy. HEPATOLOGY
1988;8:1084-1088. antagonist [11C]Ro 15-1788 (flumazenil) in baboon and human during
positron emmission tomography studies. Eur J Drug Metab Pharmacoki-18. Pomier-Layrargues G, Giguere JF, Lavoie J, Willems B, Butterworth RF.
Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic net 1991;16:141-152.
33. Swahn CG, Persson A, Pauli S. Metabolism of the benzodiazepine antag-patients with moderate or severe liver dysfunction. HEPATOLOGY 1989;
10:969-972. onist 11C-Ro 15-1788 after intravenous administration in man. Human
Psychpharmacology 1989;4:297-301.19. Janssen U, Walker S, Maier K, von Gaisberg U, Klotz U. Flumazenil
disposition and elimination in cirrhosis. Clin Pharmacol Therap 1989; 34. Lockwood AH, Yap EW, Rhoades HM, Wong WH. Altered cerebral
blood flow and glucose metabolism in patients with liver disease and46:317-323.
20. Persson A, Pauli S, Swahn CG, Halldin C, Sedvall G. Cerebral uptake minimal encephalopathy. J Cereb Blood Flow Metab 1991;11:331-336.
AID Hepa 0001 / 5p24$$$$$1 07-17-97 16:33:40 hepa WBS: Hepatology
